Veracyte Stock News

Could these health care stocks be worth looking out for as the new year approaches?

Veracyte Inc. (NASDAQ:VCYT) traded at $41.07 at close of the session on Monday, 12/20/21, made a downward move of -8.71% on its previous days price. Looking at the stock we see that its previous close was $44.99 and the beta (5Y monthly) reads 0.77 with the days price range being $40.85 $43.825. In terms Veracyte Inc. (NASDAQ: VCYT) -8.71% Decline Turns Investors Off From Company Stock Read More »

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

Fisher Asset Management LLC raised its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 292.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 957,501 shares of the biotechnology company’s stock after buying an additional 713,726 shares during the quarter. Fisher Asset Management LLC […]

Shares of Veracyte, Inc. (NASDAQ:VCYT) fell 4.5% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $40.24 and last traded at $40.33. 6,744 shares traded hands during trading, a decline of 99% from the average session volume of 756,379 shares. The stock had previously closed at $42.22. Specifically, insider […]

EFG Asset Management Americas Corp. raised its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 18.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,336 shares of the biotechnology companys stock after purchasing an additional 2,124 shares during the quarter. EFG Asset []

Veracyte, Inc. (NASDAQ:VCYT) gapped down before the market opened on Monday . The stock had previously closed at $39.22, but opened at $35.57. Veracyte shares last traded at $35.88, with a volume of 9,300 shares. Several research analysts recently issued reports on the stock. William Blair reissued an outperform rating on shares of Veracyte in []

Analysts forecast that Veracyte, Inc. (NASDAQ:VCYT) will announce $62.25 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Veracytes earnings, with the lowest sales estimate coming in at $59.10 million and the highest estimate coming in at $65.70 million. Veracyte reported sales of $34.54 million during the same quarter []

Veracyte has sharply rebounded from the COVID-19 headwinds that it faced last year and should continue growing.

Veracyte has sharply rebounded from the COVID-19 headwinds that it faced last year and should continue growing.

Veracyte, Inc. (NASDAQ:VCYT) has received a consensus recommendation of Buy from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target []

Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (

Man Group plc lifted its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 33.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,900 shares of the biotechnology companys stock after purchasing an additional 3,000 shares during the quarter. Man Group plcs holdings in Veracyte were []